2019 | Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial | Yuan J.; Mo B.; Ma Z.; Lv Y.; Cheng S.-L.; Yang Y.; Tong Z.; Wu R.; Sun S.; Cao Z.; Wu J.; Zhu D.; Chang L.; Zhang Y.; Zhao L.; Wang X.; Wang X.; Wang D.; Li X.; Peng Y.; Liang Y.; Liu H.; Xiao Z.; Lv X.; Wu S.; Dai Y.; Huang Y.; Hu Z.; Qiu C.; Li X.; Zhang S.; Li W.; Liu S.; Shi Y.; Xiong C.; Kuang J.; Xiu Q.; Cui S.; Li J.; Lin Q.; Huang W.; Wan Y.; Qimanguli, Shen C.; Xiao Y.; Wu X.; Chuang Y.C.; Perng W.C.; Tsao S.-M.; Hsu J.-Y.; Wang C.-C.; Wang J.-H.; Yeh P.-F.; Lin H.-H.; PING-HUNG KUO ; Lin M.-S.; Su W.-J.; Investigator Group of the Phase 3 Study on Oral Nemonoxacin | Journal of Microbiology, Immunology and Infection | 28 | 26 | |